AB154(Domvanalimab) is a monoclonal antibody targeting TIGIT. Domvanalimab blocks the binding of CD155 on the surface of cancer cells to TIGIT on the surface of immune cells, causing CD155 to bind to DNAM-1 protein and activate the immune signaling pathway. Clinical trials have focused on the combination therapy with PD-1 monoclonal antibody zimberelimab, mainly targeting NSCLC. Here, PDCD1 is linked to non-small cell lung carcinoma.